INBRAIN Neuroelectronics is pioneering advanced neuroelectronic therapies aimed at addressing the significant global challenge posed by neural disorders, which affect a substantial portion of the population and are a leading cause of disability and mortality. Their innovative approach combines a comprehensive neural platform that integrates hardware and data analytics to decode and modulate neural networks. This platform features skin-like, bi-directional brain-computer interfaces (BCIs) with high resolution, allowing for real-time smart neural decoding and modulation. Additionally, the company has developed an implantable compact neural processor equipped with a wireless rechargeable battery, enhancing the efficiency and effectiveness of therapies, particularly for conditions like Parkinson's Disease, for which they have received FDA Breakthrough Device Designation.

Central to INBRAIN's technology is the use of graphene, which enables the creation of flexible, high-resolution neurotechnology that significantly improves treatment efficiency. The unique properties of graphene, such as high charge injection capacity and low electrical impedance, facilitate miniaturization and enhance patient comfort while reducing power requirements. INBRAIN's commitment to safe and scalable therapies is further exemplified through their collaboration with Merck KGaA to develop INNERVIA Bioelectronics, focusing on the next generation of selective bioelectronic therapies. This holistic approach aims to address not only brain-related issues but also the broader neural system, unlocking the full potential of their innovative therapies to improve patients' lives.

Spain

Inbrain Neuroelectronics is a Neuroelectronics company that specializes in high density and high resolution graphene intelligent neural systems for central and peripheral neuroelectronic applications, with FDA breakthrough Designation.

INBRAIN Neuroelectronics

Company Details